Elevation Oncology (ELEV) has made significant progress in 2024, particularly with its antibody-drug conjugate programs targeting Claudin-18.2 and HER3. While the company’s pipeline remains in early stages, strong data readouts could lead to outsized valuations in the current market environment. ELEV’s cash position provides a runway to mid-2025, allowing for continued clinical trial advancements. However, the choice of a different payload for its ADC than the blockbuster deruxtecan introduces some uncertainty.
Results for: Biotechnology
Analysts have provided a range of perspectives on Kymera Therapeutics, with some expressing optimism while others remain cautious. The average price target has increased to $53.0, indicating a positive outlook for the company’s future performance.